Compare Ascendis Pharma A/S (ASND) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs State Street Technology Select Sector SPDR ETF — how do they compare? Ascendis Pharma A/S trades at $264.94 (market cap $17.74B), while State Street Technology Select Sector SPDR ETF trades at $180.97. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, State Street Technology Select Sector SPDR ETF nearer its low. Which is the better fit depends on your goals.
| ASND | XLK | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Sector/Thematic |
52-Week High | $277.18 | $198.21 |
52-Week Low | $163.32 | $127.49 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
XLK, the Technology Select Sector SPDR ETF, trades at $185.79, up 0.24% today, with a bullish technical signal driven by moving averages. It has gained 33% year-to-date as of July 2026, outperforming the Nasdaq-100, supported by strong tech earnings and sector inflows. A dividend of $0.23 is scheduled for June 2026.
The outlook remains positive given robust tech fundamentals and institutional optimism, but risks include market concentration, Fed policy shifts, and potential valuation pressures. Wall Street sentiment is bullish, though some investors are reducing mega-cap tech exposure ahead of key guidance updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
